National Institutes of Health
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, closing November 10, 2026.
Overview
The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies…